| 标题 |
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Chloe Orkin; Rosie Mngqibisa; Juan D. Vélez; Princy Kumar; Dominique L Braun; et al 出版日期:2026-02-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)